Interpace Biosciences, Inc.
IDXG
$1.25
$0.00280.23%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 17.33% | 11.51% | 20.50% | 26.30% | 17.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.33% | 11.51% | 20.50% | 26.30% | 17.30% |
| Cost of Revenue | 14.63% | 15.30% | 17.43% | 19.86% | 7.56% |
| Gross Profit | 19.17% | 9.03% | 22.74% | 31.11% | 25.00% |
| SG&A Expenses | 3.58% | -2.35% | -0.15% | -2.51% | -8.27% |
| Depreciation & Amortization | -97.66% | -82.22% | -57.17% | -32.13% | -21.26% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.21% | 2.02% | 4.79% | 4.83% | -4.16% |
| Operating Income | 289.22% | 410.36% | 237.57% | 173.20% | 129.15% |
| Income Before Tax | 548.49% | 264.23% | 129.67% | 119.35% | 82.36% |
| Income Tax Expenses | 0.00% | 750.00% | 21.43% | -39.29% | 750.00% |
| Earnings from Continuing Operations | 540.09% | 263.13% | 129.18% | 118.97% | 82.09% |
| Earnings from Discontinued Operations | 65.87% | 98.59% | 97.78% | 98.07% | 96.98% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 384.50% | 118.40% | 104.75% | 103.65% | 93.15% |
| EBIT | 289.22% | 410.36% | 237.57% | 173.20% | 129.15% |
| EBITDA | 125.54% | 89.19% | 7,141.51% | 399.77% | 223.99% |
| EPS Basic | 378.31% | 117.85% | 104.62% | 103.58% | 93.23% |
| Normalized Basic EPS | 576.31% | 267.31% | 127.63% | 118.38% | 85.37% |
| EPS Diluted | 374.68% | 117.60% | 104.41% | 103.41% | 93.20% |
| Normalized Diluted EPS | 573.93% | 266.46% | 127.56% | 118.36% | 85.37% |
| Average Basic Shares Outstanding | 1.53% | 1.55% | 1.66% | 1.88% | 2.06% |
| Average Diluted Shares Outstanding | 1.94% | 1.79% | 1.81% | 1.96% | 2.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
